Qure.ai has announced its collaboration with Microsoft to onboard its end-to-end lung cancer detection, measurement and management suite of AI-powered solutions onto the Precision Imaging Network. The company states that this will streamline deployment of its solutions to hospitals and health systems across the USA and support digital healthcare transformation, improved technical integrations and enhanced patient care.
According to Qure.ai, its lung cancer algorithms are built from Large Language Models and Agentic AI. The company states that its tools support workflows between radiologists, pulmonologists, interventionalists and thoracic surgery teams to accelerate the patient pathway from early detection to diagnosis and treatment. Qure.ai notes that lung cancer remains responsible for more deaths in the US than colon, breast and prostate cancers combined.
Jim Mercadante, Chief Commercial Officer, Qure.ai, said, “The Qure.ai and Microsoft collaboration brings new levels of choice and simplicity for hospitals and health systems across the USA. It will power-up access to early detection, triage and tracking to improve patient care, boost survival rates and reduce overall healthcare costs. It will also bolster a growing global roster of strategic alliances between Qure.ai, academia, governments, pharmaceutical, life science and tech companies, united in advancing the digitization of health. Recently, via a long-term partnership with AstraZeneca and the EDISON Alliance, Qure.ai achieved a unique five million scan milestone across 20 countries, applying AI to routine chest X-rays to illustrate the role AI can play in earlier lung cancer risk identification.”
Peter Durlach, Corporate VP and Chief Strategy Officer, Microsoft Health and Life Sciences, said, “The integration of Qure.ai’s AI solutions into the Precision Imaging Network will help health systems unlock new levels of efficiency – from faster detection and diagnosis to more coordinated multidisciplinary care. This collaboration reflects Microsoft’s commitment to empowering healthcare organizations with secure, scalable cloud AI solutions that enable earlier interventions, improved patient outcomes, and drive sustainable transformation across the continuum of care.”
Qure.ai reports deployments across more than 4,800 sites in over 105 countries. The company was recognised in 2025 as a TIME100 Most Influential Company for the use of AI in the diagnosis of high-burden diseases. Qure.ai has 19 FDA-cleared findings for the identification, triage and management of lung cancer and neurocritical findings. These tools support clinicians and developments across pharmaceutical and life sciences sectors.
The Qure.ai FDA-cleared lung cancer solutions can be deployed individually or as a suite. The company states that when deployed together, workflow benefits span from incidental detection of lung nodules on chest X-ray (qXR-LN), to measurement and quantification on CT (qCT-LN Quant), and patient management coordination (qTrack). Its neurocritical solution (qER) supports triage of emergency findings.